Mineralys Therapeutics Q3 EPS $(0.57) Beats $(0.76) Estimate
Portfolio Pulse from Benzinga Newsdesk
Mineralys Therapeutics reported Q3 losses of $(0.57) per share, beating the analyst consensus estimate of $(0.76) by 25 percent. This represents a 55.81 percent increase over losses from the same period last year.
November 07, 2023 | 9:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mineralys Therapeutics reported better than expected Q3 losses, which could positively impact the stock in the short term.
Mineralys Therapeutics reported a smaller loss than expected for Q3, which is generally seen as positive news by investors. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100